

In association with



society of hematologic oncology

Promoted by

ISTITUTO
SCIENTIFICO
ROMAGNOLO
PER LO STUDIO
E LA CURA
DEI TUMORI



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Istituto di Oncologia e Cura e Cura Oncologica

2 SOHO 2ND ITALIAN CONFERENCE

Rome - Italy
22 › 23 › 24 Sept. 2020

A.ROMA Lifestyle Hotel
www.sohoitaly.it

PRESIDENTS

C. Cerchione, G. Martinelli, H Kantarjian

SCIENTIFIC BOARD

**C. Cerchione, N. Daver, C. DiNardo,
A. Ferrajoli, N. Fowler, G. Garcia-Manero,
E. Jabbour, H. Kantarjian, H. Lee, T. Kadia,
M. Konopleva, G. Martinelli,
G. Musuraca, A. Ravandi, S. Verstovsek**

JOIN US!

www.sohoitaly.it

Free registration

17,5 ECM for:

Physicians, Pharmacists, Biologists, Biomedical Laboratory Technicians

Organizing secretariat



www.proeventi.it
info@proeventi.it

Follow us



#SOHOITALY20

Registration




With the patronage of



SIE
Società Italiana di
Ematologia




MARTINELLI GIOVANNI



As of 1 January 2018, Professor Giovanni Martinelli is scientific director of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl – IRCCS, in Meldola (FC), Italy. Until December 2017, Professor Giovanni Martinelli was associate professor of Hematology at the Institute of Hematology “L. & A. Seragnoli”, Azienda Ospedaliera S. Orsola-Malpighi at the University of Bologna, Italy. His main fields of research are AML, ALL and CML, including research on targeted therapies in major hematological syndromes: Acute L e u - kemias, CML (both Philadelphia-chromosome positive and non-positive), and hypereosinophilic syndrome.

CERCHIONE CLAUDIO



Since 2018, he works in Hematology Unit of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS. He also has spent international research experiences in Friedrich-wilhelms universität, Bonn, Germany, in Universitade de Coimbra, Portugal, collaborating in their clinical and research projects, and in MD Anderson Cancer Center, Houston, USA, where he was nominated Ambassador of SOHO (Society of Hematologic Oncology). He is member of the editorial boards of many scientific journals, and member of several international societies, including the Society of Hematologic Oncology (SOHO), American Society of Hematology (ASH), European Hematology Association (EHA) and Italian Society of Hematology (SIE). In 2018/2019 he was nominated by EHA as one of the winners of Clinical Research Training in Hematology.

KANTARJIAN HAGOP



Hagop Kantarjian, M.D. is professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he is also the Samsung Distinguished Leukemia Chair in Cancer Medicine. He is also a non-resident fellow in health policy at the Rice University Baker Institute. Doctor Kantarjian has received several prestigious honours and awards including the 37th Jeffrey A Gottlieb Memorial Award (2012), the John Mendelsohn Lifetime Scientific Achievement Award (2008), the Joseph H. Burchenal Memorial Award (2013), the Charles A. LeMaistre, M.D. Outstanding Achievement Award in Cancer (2014), and America’s Top Doctors, Castle Connolly Medical (2003-present). He was also selected the top Castle Connolly National Physician of the Year Award for Lifetime Achievement (2014). Doctor Kantarjian’s research focuses on translational-clinical developmental therapeutics

DAVER NAVAL G.



“Dr Naval Daver is an Associate Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center. He is a clinical investigator with a focus on molecular and immune therapies in AML and myeloid disease and is principal investigator on >25 ongoing institutional, national and international clinical trials in these diseases. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanism of resistance. He is especially interested in developing monoclonal and bispecific antibodies, immune checkpoint and vaccine based approaches, as well as targeted and apoptotic therapies in AML and is leading a number of these trials at MDACC. Dr Daver has published >240 peer-reviewed manuscripts and is on the editorial board of numerous hematology journals.”

DiNARDO COURTNEY



Dr. DiNardo interests are focused on inherited predispositions to hematologic malignancies. This interest led to the development of one of the first dedicated clinics for evaluation of families with hematologic malignancies in the country (Hereditary Hematologic Malignancy Clinic—HHMC) in April 2014. The HHMC provides research-based opportunities for scientific discovery through whole exome sequencing families with a strong history of hematologic malignancies including the potential for novel gene discovery. My research in the evolving clinical phenotype and treatment outcomes of IDH1 and IDH2 mutations in myeloid malignancies has yielded numerous publications and national/international IDH-inhibitor trials. My expertise in myeloid malignancy metabolomics has also driven my research related to therapeutic targeting of glutamine metabolism in myelodysplastic syndrome.

FERRAJOLI ALESSANDRA



Dr. Ferrajoli is an academic hematologist/oncologist practicing in the Leukemia Department at the University of Texas, MD Anderson since 1998. Her main area of interest includes the treatment and biology of chronic lymphocytic leukemia and its variants, and treatment of elderly patients with acute and chronic leukemia. In these fields Dr. Ferrajoli has authored and co-authored more than two hundred and fifty publications in peer reviewed journals.

She serves on numerous journal editorial boards and grant proposal study sessions for several US and European Agencies.

FOWLER NATHAN H.



His interest in immunomodulatory agents began during my hematology/oncology fellowship at Georgetown University Hospital, where he helped to develop some of the first protocols to use lenalidomide in CLL. Since joining the faculty at MD Anderson Cancer Center, the goal of his clinical research has been to further develop novel therapeutic regimens utilizing immunomodulatory agents to benefit patients with low grade non-Hodgkins lymphoma. He serves as the chairman of several phase I and investigator-initiated phase II trials for patients with non-Hodgkins lymphoma which includes leading the largest clinical study to use immunomodulatory drugs for untreated low grade lymphoma.

GARCIA-MANERO GUILLERMO



Guillermo Garcia-Manero, M.D., is a physician-scientist specializing in state-of-the-art treatments for leukemia. His research focuses on myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), and his goal is develop and validate new therapeutics to treat these deadly diseases. He leads teams of clinicians, medical fellows, nurses, physician assistants and researchers to conduct pre-clinical, translational, and clinical studies. The goal of these studies is to understand, treat, and eventually cure MDS, AML and other leukemias.

JABBOUR ELIAS



Dr. Jabbour joined the MD Anderson Cancer Center faculty in 2007 and is currently a Professor of Medicine in the Department of Leukemia. He is actively involved in developmental therapeutics research in leukemia. Over the past 5 years he has assisted in developing chemotherapeutic and biologic agents in leukemias and contributed to the development of others. These include: 1) the Hyper CVAD-ofatumumab regimen in ALL; 2) clofarabine in myeloid malignancies; 3) hypomethylating agents in AML and MDS; 4) Tyrosine kinase therapy in CML; and 5) triple therapy in AML.

LEE HANS C.



Hans C. Lee, MD, is an Assistant Professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center in Houston, Texas where he focuses his efforts on the clinical care and research of patients with plasma cell dyscrasias. He has a particular interest and focus on early phase clinical trials and novel therapeutic approaches to relapsed and/or refractory multiple myeloma.

KADIA TAPAN M.



Dr. Tapan Kadia is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is actively involved in clinical and translational research for the treatment of patients with leukemia. His particular focus is in developmental therapeutics in acute leukemia, including individualized frontline therapy, biologically rational targeted therapy, and longer term maintenance strategies in AML and ALL. He is primary investigator on numerous trials in acute myeloid leukemia, T-cell leukemias, bone marrow failure states, and is a leader in these.

KONOPLIVA MARINA




Dr. Konopleva is a Physician-Scientist, Professor, and active member of the clinical faculty in the Departments of Leukemia and Stem Cell Transplantation. Her laboratory is studying novel agents in acute myeloid and lymphocytic leukemias, focusing on BCL-2 targeting and agents targeting leukemic microenvironment and metabolism. Dr. Konopleva has extended her research to include clinical translational investigations and has developed clinical trials based on laboratory discoveries. These include BCL-2 inhibitor venetoclax, inhibitor of oxidative phosphorylation, CXCR4 inhibitors, AKT and mTOR inhibitors and hypoxia-activated prodrugs. She has also been an active mentor to trainees including undergraduate, medical and graduate students, post-doctoral fellows who have trained under her direction in support of her various laboratory grants and projects.

MUSURACA GERARDO




Dr. Musuraca is the Chief of Hematology Unit at IRST – IRCCS, in Meldola (FC), Italy. After a degree cum laude at the University of Bologna and a specialization in Hematology, since January 2006 he has been a PhD student in Clinical and Experimental Hematology at the University of Bologna. In 2007 he began the Clinical activity and research at Cancer Institute of Romagna. He is also Abstracts Reviewer and moderator on lymphoma, preclinical and biological agents of the American Society of Hematology meeting (ASH) and in December 2011 he reached a highly specialized position on Lymphomas at the Cancer Institute of Romagna. Dr. Musuraca is Coauthor of more than 43 publications and Since 2001 he is involved in more than 200 multicenter national and international clinical trials performed in onco-hematology (Lymphomas), according to the FDA regulations and/or ICH-GCP guidelines.

RAVANDI-KASHANI FARHAD



Dr. Farhad Ravandi is Janiece and Stephen A. Lasher Professor of Medicine and Chief of Section of Developmental Therapeutics in the Department of Leukemia at the University of Texas – M. D. Anderson Cancer Center. Dr. Ravandi is board certified in Internal Medicine, Hematology and Medical Oncology. His main areas of interests are therapy of acute myeloid leukemia, as well as rare leukemias including Philadelphia positive acute lymphoblastic leukemia, hairy cell leukemia and T-cell leukemias. He has authored several book chapters and many articles in peer-reviewed journals. He is a member of several professional societies including the American Society of Hematology, American Society of Clinical Oncology, and Society of Hematological Oncology and is a member of editorial board of several journals.

VERSTOVSEK SRDAN



Dr. Verstovsek is the United Energy Resources, Inc., Professor of Medicine and a hematologist-oncologist at MD Anderson, he is a global leader in myeloproliferative neoplasms (MPN) and the Founder/ Director of the largest MPN Clinical Research Center worldwide. He has achieved international acclaim for his leadership in developing landmark MPN therapeutics. He is leading pivotal phase 3 trials for several promising myelofibrosis medications. Dr. Verstovsek received several distinguished awards, including the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research (2017) and the Seventh Annual Irwin H. Krakoff Award for Excellence in Clinical Research (2013). He was elected member of The American Society for Clinical Investigation (2015) and received the Celgene 2010 Young Investigator Award for Clinical Research.

DAY 1

22.
09.
2020

1 - 4 Sessions

Opening Session

ITA 12.00 - 13.40 / TX 05.00 - 06.40 AM

12.00-12.30

Opening Lunch SOHO Italy

12.30-13.00

Special Lecture: COVID-19 and Hematologic Malignancies

F. Locatelli

13.00-13.30

Open questions

Chairs: C. Cerchione, G. Martinelli

13.30 - 13.40

Welcome and Introduction What is Italian SOHO

C. Cerchione, N. Daver, E. Jabbour, H. Kantarjian,
M. Konopleva, G. Martinelli

SESSION

01.

1st session ITA 13.40 - 15.20 / TX 06.40 - 08.20 AM

Acute Lymphoblastic Leukemia – State of the art

C. Cerchione, N. Daver, E. Jabbour, H. Kantarjian,
M. Konopleva, G. Martinelli

13.40 - 13.55

ALL: State of the art in MD Anderson Cancer Center

H. Kantarjian

13.55 - 14.05

ALL: State of the art in Europe

G. Martinelli

14.05-14.20

Optimizing adult and Elderly frontline ALL therapy:
Role of immunochemotherapy

E. Jabbour

14.20-14.35

ALL: Ph-like and new genetic subtypes and treatment
implications

M. Konopleva

14.35-14.45

MRD when and how to tailor therapy: role of
allogenic stem cell transplantation

A. Rambaldi

14.45-15.00

Lecture: Role of NGS in Acute Leukemias

T. Haferlach

15.00-15.20

Question and Answers

SESSION

02.

2nd session ITA 15.20 - 16.40 / TX 08.20 - 09.40 AM

Acute Lymphoblastic Leukemia – Ph positive ALL

E. Jabbour - M. Konopleva – G. Martinelli

Ph-positive ALL debate:

15.20-15.30

How could we potentiate monoclonal
antibodies' activity?

R. Foà

15.30-15.45

CART-cells Therapy: Novel generation, Fast-off, Dual
CART-cells

J. Ribera

15.45-15.55

Novel therapeutic strategies on Acute Leukemia
based on synthetic lethality

A.Ghelli

15.55-16.05

Triple negative B-ALL

A. Ferrari

16.05-16.25

Question and Answers

16.25 - 16.40

Coffee break

SESSION

03.

3rd session ITA 16.40 - 18.10 / TX 09.40 - 11.10 AM

Acute Lymphoblastic Leukemia – Beyond ALL and near future

C. Cerchione – H. Kantarjian

16.40- 16.55

Diagnostic approaches for Ph-like B-ALL

S. Konoplev

16.55-17.05

Infections in Acute Leukemias

L. Pagano

17.05-17.15

Morphology in Acute Leukemias and hematologic
malignancies

G. Zini

17.15-17.25

Monoclonal antibodies: real life and new combination trials

C. Papayannidis

17.25-17.35

Novel monoclonal antibodies combinations and near future of ALL in Italy

F. Lanza

17.35-17.50

Future of ALL therapy

H. Kantarjian

17.50-18.10

Question and Answers

SESSION

04.

4th session ITA18.10- 18.55 / TX 11.10- 11.55 AM

CAR-T session

F. Ciceri - F. Locatelli

18.10-18.20

CAR-T in Europe – State of the art

F. Locatelli

18.20-18.30

New CAR-T cell clinical trials for patients with Leukemia or Lymphoma: room for improvement

C. Quintarelli

18.30-18.40

Future of CAR-T cells for hematologic and non-hematologic malignancies

F. Ciceri

18.40-18.55

Questions and Answers

DAY 2

23.
09.
2020

5 - 12 Sessions

Meet the experts sessions

ITA 07.30 - 08.30 / TX 00.30 -01.30 AM

AML: H. Kantarjian/F. Ravandi

ALL: M. Konopleva/ G. Martinelli

CML: E. Jabbour/G. Saglio

CLL: A. Ferrajoli/A. Cuneo

Immunotherapy: N. Daver/A. Isidori

SESSION

05.

5th session ITA 08.30 - 09.50 / TX 01.30 - 02.50 AM

Health Management System

M. Altini – E. Crocetti

08.30-08.40

New frontiers in health management

M. Altini

08.40-08.50

Role of Oncology registries in Italy: Importance for patients and future

E. Crocetti

08.50-09.00

Clinical Trials Management: present and future

O. Nanni

09.00-09.10

Multidisciplinary approach in IRST

OncoHematology Department

G.L. Frassinetti

09.10-09.20

Drug Management in Italy: near future
of Oncopharmacist

C. Masini

09.20-09.30

My life against cancer - Prof. Amadori and
Oncology development in Tanzania (in memory of
D. Amadori)

P. Serra

09.30-09.50

Question and Answers

SESSION

06.

6th session ITA 09.50 - 10.45 / TX 02.50 - 03.45 AM

Selected Oral Presentations

C. Cerchione – G. Martinelli

09.50-09.55

Molecular Minimal Residual Disease monitoring in
NPM1-mutated Acute Myeloid Leukemia: a single
institution experience

L. Cesini

09.55-10.00

Bromodomain and extra-terminal mofit proteins
regulate linear and circular PVT1 in Acute Myeloid
Leukemia cells under normoxi and hypoxia

M. Gheti

10.00-10.05

Blockade of Oncogenic Notch1 with the new serca
inhibitor CAD204520 in T-Cell Acute Lymphoblastic
Leukemia

M. Marchesini

10.05-10.10

Diffuse Large B-cell Lymphoma of the Uterus: A Propensity Score Matched Analysis of the Texas Cancer Registry

A. Ensor

10.10-10.15

CD20-Negative Diffuse Large B-Cell Lymphoma Subtype: a look at Texas Cancer Registry

K. Anand

10.15-10.20

Pandora box of Lymphomas in Spleen

S. Jain

10.20-10.25

High dose chemotherapy and autologous stem cell transplantation in Multiple Myeloma patients over 70 years: "GIMEMA Working Group Lazio experience

A. Rago

10.25-10.30

DREAMM-2: single-agent belantamab mafodotin in patients with relapsed/refractory Multiple Myeloma (RRMM), including subgroups with renal impairment (RI) and High-Risk (HR) cytogenetics

S. Lonial

10.30-10.35

Impact of prolonged dose delays on response with belantamab mafodotin (BELAMAF; GSK2857916) treatment in DREAMM-2 study: 13-month Follow-up

A.D. Cohen

10.35-10.40

MDS in Ukraine: A 25-year Single Institution Analysis

T.S. Ivanivskaya

Open Coffee break

07.

Acute Myeloid Leukemia Toward individualized treatment

C. Mecucci - C. Papayannidis

10.45-11.00

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

I. Iacobucci

11.00-11.10

New insights into the biology of Acute Myeloid Leukemia with mutated NPM1

L. Brunetti

11.10-11.20

Proapoptotic pathways in AML

S. Galimberti

11.20-11.30

Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients

R.M. Lemoli

11.30-11.50

Question and Answers

SESSION

8th session ITA 11.50 - 12.35 / TX 04.50 - 05.35 AM

08.

Acute Myeloid Leukemia Genetic profiling, Metabolism, MRD and novel agents: What's new?

A. De La Fuente - A. Isidori

11.50-12.00

Metabolism in AML

G. Simonetti

12.00-12.10

Assessment of MRD in AML and integrating MRD into
treatment: Role of new techniques

F. Buccisano

12.10-12.20

Target therapies in frontline and relapsed AML

M.P. Martelli

12.20-12.35

Question and Answers

SESSION

09.

9th session ITA12.35 - 14.00 / TX 05.35 - 7.00 AM

Chronic Lymphocytic Leukemia - State of the art

A. Cuneo - A. Ferrajoli

12.35-12.50

How I treat CLL: State of the Art in USA

A. Ferrajoli

12.50-13.00

How I treat CLL: State of the Art in Italy

A. Cuneo

13.00-13.10

Management of relapsed/refractory disease:

Novel agents

P. Ghia

13.10-13.20

Role of MRD in CLL

M. Massaia

13.20-13.40

Biology and management of Richter syndrome

G. Gaidano

13.40-14.00

Question and Answers

ITA 14.00 - 15.00 / TX 07.00 - 08-00 AM

Lunch Symposium sponsored by
Jazz Pharmaceuticals extra ECM (CME)

CPX-351 in High Risk AML: from bench to bedside

Chair: G. Martinelli

14.00-14.20

CPX-351: new advanced liposomal formulation or new drug?

G. Martinelli

14.20-14.40

Long-term data from Pivotal Trials

C. Cerchione

14.40-15.00

RWE data from international and national experience

R.M. Lemoli

SESSION

10.

10th session ITA 15.00 - 17.00/ TX 08.00 - 10.00 AM

Acute Myeloid Leukemia State of the art

H. Kantarjian – F. Ravandi

15.00-15.15

How I treat AML in MD Anderson Cancer Center

H. Kantarjian

15.15-15.25

How I treat AML in Europe

G. Martinelli

15.25-15.40

Incorporating novel antibodies as target therapies in treatment of older AML

F. Ravandi

15.40-16.00
Updates in Immunotherapy and FLT3 inhibitors in AML
N. Daver

16.00-16.10
How I manage NPM1 AML
B. Falini

16.10-16.25
Maintenance in AML: State of the art
F. Ravandi

16.25-16.45
Question and Answers

16.45-17.00
Coffee break

SESSION

11.

11th session ITA 17.00 - 18.10 / TX 10.00 - 11.10 AM

Acute Myeloid Leukemia State of the art in Elderly patients

N. Daver, C. DiNardo

17.00-17.15
How I manage Elderly AML in MD Anderson Cancer Center
T. Kadia

17.15-17.25
How I manage Elderly AML in Italy
A. Isidori

17.25-17.40
IDH-inhibitor based therapies in AML
C. DiNardo

17.40-17.50
Frontline fit patients' treatment 3+7 is not anymore standard of care
F. Ferrara

17.50-18.10
Question and Answers

SESSION

12.

12th session ITA 18.10 - 19.30 TX 11.10 AM - 12.30 PM Acute Myeloid Leukemia Old certainties versus New frontiers

C. Cerchione - G. Martinelli

18.10-18.20

Role of allogenic transplant in novel agents era

A. Olivieri

18.20-18.30

Role of postSCT maintenance in AML

A. Sperotto

18.30-18.40

Environment-mediated drug resistance in AML

C. Cerchione

18.40-18.55

Phase 4 studies in Spain

A. De La Fuente

18.55-19.10

Future of Acute Myeloid Leukemia

H. Kantarjian

19.10-19.30

Question and Answers

DAY 3

24.
09.
2020

13 - 21 Sessions

Meet the experts sessions

ITA 07.30 - 08.30 / TX 00.30 -01.30 AM

MDS: G. Garcia-Manero/V. Santini

MPN: S. Verstovsek/A. Lucchesi

MM: KC Anderson/C. Cerchione

Smoldering MM: M.V. Mateos

NHL: P. Martin/G. Musuraca

HD: N. Fowler/C. Carlo-Stella

SESSION

13.

13th session ITA 08.30 - 09.15 / TX 01.30 - 02.15 AM

Multiple Myeloma – New Insights into biology and genetic profiling

N. Bolli - C. Terragna

08.30-08.40

New insights into biology of MM, SMM and MGUS

C. Terragna

08.40-08.50

New insights in anti-angiogenesis in Multiple Myeloma

A. Solimando

08.50-09.00

Genetic profiling of Multiple Myeloma in novel agents era

N. Bolli

09.00-09.15

Question and Answers

SESSION

14th session ITA 09.15 - 10.35 / TX 02.15 - 03.35 AM

14.

Multiple Myeloma – Hot topics in novel agents era

C. Cerchione - M.V. Mateos

09.15-09.30

How I treat smoldering MM

M.V. Mateos

09.30-09.40

**How I manage newly diagnosed
transplant-eligible MM**

V. Montefusco

09.40-09.50

How I manage unfit/frail patients

D. Derudas

09.50-10.00

Importance of imaging in the era of novel agents

E. Zamagni

10.00-10.20

Question and Answers

10.20-10.35

Coffee break

SESSION

15th session ITA 10.35 - 11.35 / TX 03.35 - 04.35 AM

15.

Multiple Myeloma – Novel agents and ASCT versus CAR-T and near future

H. Lee . M. Martino

10.35-10.45

Role of autologous transplant in MM in novel agents era

M.T. Petrucci

10.45-10.55

Balancing efficacy and tolerability in novel Agents era

P. Tosi

10.55-11.05

CAR-T cells therapies in MM

M. Martino

11.05-11.15

New drugs on the Horizon

F. Di Raimondo

11.15-11.35

Question and Answers

SESSION

16th session ITA 11.35 - 13.05 / TX 04.35 - 06.05 AM

16. Multiple Myeloma State of the art

K.C. Anderson - C. Cerchione

11.35-11.45

Multiple Myeloma: State of the art in Europe

C. Cerchione

11.45-12.00

Multiple Myeloma: State of the art in USA

K.C. Anderson

12.00-12.15

Antibody-Drug Conjugates and Bispecific Antibodies
in Multiple Myeloma

H. Lee

12.15-12.30

Near future of Multiple Myeloma in Europe

M.V. Mateos

12.30-12.45

Near future of Multiple Myeloma in USA

K.C. Anderson

12.45-13.05

Question and Answers

ITA 13.05 - 14.00 / TX 06.05 - 07.00 AM

Lunch Symposia

SESSION

17.

17th session ITA 14.00 - 15.20 / TX 07.00 - 08.20 AM

Non Hodgkin Lymphoma State of the art

P. Martin - N. Fowler - G. Musuraca

How I manage DLBCL lymphoma

14.00-14.15

in USA 

P. Martin

14.15-14.25

in Italy 

G. Musuraca

14.25-14.35

Macrophage oriented prognostication
and therapy in DLBCL

S. Ciavarella

How I manage follicular, mantle cell and marginal lymphoma

14.35-14.50

in USA 

N. Fowler

14.50-15.00

in Italy 

S. Luminari

15.00-15.20

Question and Answers

18.

Hodgkin Lymphoma and Biology of lymphomas

J. Leonard - E. Derenzini

How I manage Hodgkin disease

15.20-15.35

in USA 

J. Leonard

15.35-15.45

in Italy 

C. Carlo-Stella

15.45-15.55

Microenvironment-driven metabolic rewiring in
Lymphomas

A. Romano

15.55-16.05

Challenges and new opportunities to manage
Waldestrom disease in Italy

A. Tedeschi

16.05-16.15

Lecture: Genomic alterations of ribosomal protein
genes in diffuse large B cell lymphoma

E. Derenzini

16.15-16.25

Near future of Hodgkin Lymphomas

A. Pinto

16.25-16.45

Question and Answers

16.45-17.00

Coffee break

19.

19th session ITA 17.00 - 18.25 / 10.00 - 11.25 AM Chronic Myeloid Leukemia

E. Jabbour – G. Saglio

17.00-17.15

How I manage CML in MDACC

E. Jabbour

17.15-17.25

How I manage CML in Italy

G. Saglio

17.25-17.35

Management of relapsed/refractory CML and advanced phases

G. Rosti

17.35-17.45

Treatment-free remission where and when?

M. Malagola

17.45-17.55

TFR: lights and shadows

E. Abruzzese

17.55-18.05

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

F. Pane

18.05-18.25

Question and Answers

SESSION

20th session ITA 18.25 - 19.15 / TX 11.25 AM - 12.15 PM

20.

New insights in MPNs

A. Lucchesi - S. Verstovsek

18.25-18.40

**Management of Myeloproliferative
Neoplasms**

S. Verstovsek

18.40-18.50

Novel therapeutic approaches in PV and ET

A. Lucchesi

18.50-19.00

New insights into biology of MPN

A.R. Migliaccio

19.00-19.15

Questions and Answers

21.

21st session ITA 19.15 - 20.30 / TX 12.15 - 01.30 PM

Myelodysplastic syndromes: State of the art

G. Garcia-Manero - V. Santini

19.15-19.25

Myelodysplastic Syndromes

State of the art in Europe

V. Santini

19.25-19.40

Myelodysplastic Syndromes

State of the art in USA

Emerging frontline HMA based regimens

G. Garcia-Manero

19.40-19.50

Biology and importance of staging systems

M. Della Porta

19.50-20.00

Patient centred approach for the treatment of

MSD: Importance of quality of life

E. Oliva

20.00-20.10

Approach to Management of Lower-risk MDS

P. Musto

20.10-20.30

Questions and Answers

See you in September 2021

Supported by an unrestricted educational grant from



BeiGene



Jazz Pharmaceuticals®

abbvie



janssen  Oncology

PHARMACEUTICAL COMPANIES OF 

Stemline

neovii



Daiichi-Sankyo

 Karyopharm®
Therapeutics

Follow us!

The use of social media is extremely important to build a stronger relationship and to improve the interaction between speakers and attendees, so do not forget to use them!

Our official hashtag is **#SOHOITALY20** !

You can use it on Facebook, Twitter, Instagram and LinkedIn.

Put your like on our social pages and follow us!

You can tweet with:

@sohoitaly

@SocietyofHemOnc

@IRSTufficiale

@MDAndersonNews

@pro_eventi

@GMartinelli2

@DottorClaudio

@DrHKantarjian

@Daver_Leukemia

@DrNathanFowler

@garciamanero

@TapKadia

Follow us



#SOHOITALY20

Enjoy and share your experience!

in association with



society of hematologic oncology

**Organizing Secretariat
Provider ECM n. 2773**



**www.proeventi.it
info@proeventi.it**